Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Rare Diseases Treatment Market, by Drug Type
1.4.2 North America Rare Diseases Treatment Market, by Distribution Channel
1.4.3 North America Rare Diseases Treatment Market, by Route of Administration
1.4.4 North America Rare Diseases Treatment Market, by Therapeutic Area
1.4.5 North America Rare Diseases Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
Chapter 4. North America Rare Diseases Treatment Market by Drug Type
4.1 North America Biologics Market by Country
4.2 North America Biosimilar Market by Country
4.3 North America Small Molecule Market by Country
Chapter 5. North America Rare Diseases Treatment Market by Distribution Channel
5.1 North America Specialty Pharmacy Market by Country
5.2 North America Hospital Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Rare Diseases Treatment Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Rare Diseases Treatment Market by Therapeutic Area
7.1 North America Cancer Market by Country
7.2 North America Cardiovascular Conditions Market by Country
7.3 North America Infectious Diseases Market by Country
7.4 North America Musculoskeletal Conditions Market by Country
7.5 North America Endocrine Disorders Market by Country
7.6 North America Metabolic Disorders Market by Country
7.7 North America Hematologic Disorders Market by Country
7.8 North America Neurological Conditions Market by Country
7.9 North America Others Market by Country
Chapter 8. North America Rare Diseases Treatment Market by Country
8.1 US Rare Diseases Treatment Market
8.1.1 US Rare Diseases Treatment Market by Drug Type
8.1.2 US Rare Diseases Treatment Market by Distribution Channel
8.1.3 US Rare Diseases Treatment Market by Route of Administration
8.1.4 US Rare Diseases Treatment Market by Therapeutic Area
8.2 Canada Rare Diseases Treatment Market
8.2.1 Canada Rare Diseases Treatment Market by Drug Type
8.2.2 Canada Rare Diseases Treatment Market by Distribution Channel
8.2.3 Canada Rare Diseases Treatment Market by Route of Administration
8.2.4 Canada Rare Diseases Treatment Market by Therapeutic Area
8.3 Mexico Rare Diseases Treatment Market
8.3.1 Mexico Rare Diseases Treatment Market by Drug Type
8.3.2 Mexico Rare Diseases Treatment Market by Distribution Channel
8.3.3 Mexico Rare Diseases Treatment Market by Route of Administration
8.3.4 Mexico Rare Diseases Treatment Market by Therapeutic Area
8.4 Rest of North America Rare Diseases Treatment Market
8.4.1 Rest of North America Rare Diseases Treatment Market by Drug Type
8.4.2 Rest of North America Rare Diseases Treatment Market by Distribution Channel
8.4.3 Rest of North America Rare Diseases Treatment Market by Route of Administration
8.4.4 Rest of North America Rare Diseases Treatment Market by Therapeutic Area
Chapter 9. Company Profiles
9.1 AbbVie, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Acquisition and Mergers:
9.3 Bayer AG
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Approval and Trails:
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.6 Bristol Myers Squibb Company
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Acquisition and Mergers:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Acquisitions and Mergers:
9.8 AstraZeneca PLC
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisition and Mergers:
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisition and Mergers:
9.10. PTC Therapeutics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Acquisition and Mergers:
Unique Offerings 